KLRA Kailera Therapeutics, Inc. - Common stock
NASDAQ · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 12, 2026KLRA Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
KLRA Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | KLRA | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/B (MRQ) | 1.2 | · | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
Data fundamental belum cukup untuk menghitung grup rasio ini.
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | KLRA | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 11.1 | · | · | · |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Data fundamental belum cukup untuk menghitung grup rasio ini.
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
Data fundamental belum cukup untuk menghitung grup rasio ini.
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 12, 2026 | $-1.09 | $-0.77 | -42.5% |
| 31 Maret 2026 | $-0.64 | $-0.69 | 7.3% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Neraca
| Metrik | Tren | 2025 |
|---|---|---|
| Cash & Equivalents | $160M | |
| Short-term Investments | $386M | |
| Prepaid Expense | $11M | |
| Other Current Assets | $2M | |
| Current Assets | $558M | |
| PP&E (Net) | $2M | |
| Other Non-current Assets | $3M | |
| Total Assets | $692M | |
| Accounts Payable | $8M | |
| Accrued Liabilities | $38M | |
| Current Liabilities | $46M | |
| Capital Leases | $10M | |
| Other Non-current Liabilities | $270.0K | |
| Total Liabilities | $56M | |
| Common Stock | $0 | |
| Retained Earnings | $-369M | |
| AOCI | $229.0K | |
| Stockholders' Equity | $-356M | |
| Liabilities + Equity | $692M | |
| Shares Outstanding | 19,048 |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| R&D Expense | $101M | $71M | $20M | $10M | |
| SG&A Expense | $20M | $14M | $11M | $10M | |
| Operating Expenses | $121M | $85M | $31M | $20M | |
| Operating Income | $-121M | $-85M | $-31M | $-20M | |
| Other Non-op | $72.0K | $6M | $-422.0K | $2M | |
| Net Income | $-111M | $-79M | $-29M | $-18M | |
| EPS (Basic) | $-1.09 | $-3650.00 | $-28947.00 | $-17983.00 | |
| EPS (Diluted) | $-1.09 | $-3650.00 | $-28947.00 | $-17983.00 | |
| Shares (Basic) | 102,226,608 | 21,607 | 1 | 1 | |
| Shares (Diluted) | 102,226,608 | 21,607 | 1 | 1 | |
| EBITDA | $-121M | $-85M | · | · |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $130M | $112M | · | · | |
| Short-term Investments | $786M | $407M | · | · | |
| Prepaid Expense | $12M | $11M | · | · | |
| Other Current Assets | $395.0K | $360.0K | · | · | |
| Current Assets | $929M | $530M | · | · | |
| PP&E (Net) | $2M | $2M | · | · | |
| Other Non-current Assets | $90.0K | $6M | · | · | |
| Total Assets | $1.21B | $625M | · | · | |
| Accounts Payable | $19M | $7M | · | · | |
| Accrued Liabilities | $63M | $47M | · | · | |
| Current Liabilities | $84M | $55M | · | · | |
| Capital Leases | $9M | $9M | · | · | |
| Other Non-current Liabilities | $135.0K | $201.0K | · | · | |
| Total Liabilities | $93M | $64M | · | · | |
| Common Stock | $0 | $0 | · | · | |
| Retained Earnings | $-559M | $-448M | · | · | |
| AOCI | $-2M | $-532.0K | · | · | |
| Stockholders' Equity | $1.12B | $-432M | · | · | |
| Liabilities + Equity | $1.21B | $625M | · | · | |
| Shares Outstanding | 129,620,370 | 29,953 | · | · |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| D&A | $101.0K | $101.0K | $62.0K | $63.0K | |
| Stock-based Comp | $8M | $4M | $2M | $2M | |
| Other Non-cash | · | $7M | · | · | |
| Operating Cash Flow | $-78M | $-68M | $-26M | $-18M | |
| Investing Cash Flow | $-571M | $23M | $-74M | $-54M | |
| Financing Cash Flow | $667M | $-3M | $100M | $0 |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| ROA | -18.4% | -25.2% | · | · | |
| ROE | -19.9% | 36.5% | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Current Ratio | 11.1 | 9.7 | · | · | |
| Quick Ratio | · | 9.5 | · | · |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Book Value / Share | · | $-14425.53 | · | · | |
| Cash Flow / Share | · | $-3161.48 | · | · | |
| Cash / Share | $1.01 | $3733.38 | · | · |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Market Cap | $2.86B | · | · | · | |
| P/B | 2.6 | · | · | · | |
| P / Tangible Book | 2.6 | · | · | · |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Data fundamental belum cukup untuk membuat laporan ini.
Data fundamental belum cukup untuk membuat laporan ini.
Data fundamental belum cukup untuk membuat laporan ini.
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| BCLS Fund IV Investments, L.P. | 23 April 2026 | 17,43% | Pengajuan awal | Investasi pasif | SEC |
| BCPE Perseus Investor, LP | 23 April 2026 | 20,27% | Pengajuan awal | Investasi pasif | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 16 orang dalam · 9 pejabat · 7 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Ronald C Renaud JR | CEO & President | 9 Juni 2026 M | 38.094 | 0 | 0 | $0 |
| Douglas W. Pagan | Chief Financial Officer | 16 April 2026 A | · | 0 | 0 | $0 |
| Paul D. Burgess | Chief Operating Officer & Chief Business Officer | 16 April 2026 A | · | 0 | 0 | $0 |
| Nur Nicholson | Chief Technology Officer | 7 Sep. 2026 A | · | 0 | 0 | $0 |
| Kathleen Tregoning | Chief Corporate Affairs Officer | 6 Juli 2026 A | · | 0 | 0 | $0 |
| Scott M. Wasserman | Chief Medical Officer | 16 April 2026 A | · | 0 | 0 | $0 |
| Jamie Beth Coleman | Chief Commercial Officer | 16 April 2026 A | · | 0 | 0 | $0 |
| Scott Akamine | Chief Legal Officer | 16 April 2026 A | · | 0 | 0 | $0 |
| Paula Cloghessy | Chief People Officer | 16 April 2026 A | · | 0 | 0 | $0 |
| Christopher Hite | Direktur | 16 April 2026 A | · | 0 | 0 | $0 |
| Frank Clyburn | Direktur | 16 April 2026 A | · | 0 | 0 | $0 |
| Andrew T. Kaplan | Direktur | 16 April 2026 A | 26.255.581 | 1 | 0 | $134.375.008 |
| Adam Koppel | Direktur | 16 April 2026 A | 22.583.268 | 1 | 0 | $25.000.000 |
| Martin Mackay | Direktur | 16 April 2026 A | · | 0 | 0 | $0 |
| John F Milligan | Direktur | 16 April 2026 A | · | 0 | 0 | $0 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pemilik 10% | 20 April 2026 C | 2.034.133 | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 16 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,04% | 34.051 SH | 19 Agu 2026 | Harian |
| IWO · iShares Trust | 0,03% | 291.357 SH | 11 Sep. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,03% | 265.577 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,02% | 1.171.919 SH | 11 Sep. 2026 | Harian |
| VBK · VANGUARD INDEX FUNDS | 0,02% | 487.994 SH | 19 Agu 2026 | Harian |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 12.500 SH | 19 Agu 2026 | Harian |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,02% | 3.630 SH | 2 Okt. 2026 | Harian |
| WSML · iShares Trust | 0,01% | 4.536 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 476.091 SH | 19 Agu 2026 | Harian |
| VB · VANGUARD INDEX FUNDS | 0,01% | 848.546 SH | 19 Agu 2026 | Harian |
| ITOT · iShares Trust | 0,00% | 62.160 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 12.366 SH | 10 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.180.411 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.839 SH | 19 Agu 2026 | Harian |
| IWN · iShares Trust | · | 135.762 SH | 11 Sep. 2026 | Harian |
| ISCB · iShares Trust | · | 1.996 SH | 11 Sep. 2026 | Harian |
KLRA Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
Target Harga 12 Bulan
5 analis · 2026-09-29Target rata-rata $42.40 +308,1%
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| KLRA | · | · | · | · | · | · |
| INBX | $1.15B | -8.7 | 550.0% | -10773.5% | -365.9% | · |
| COAG | · | · | · | · | · | · |
| TYRA | $1.41B | -13.1 | · | · | -42.7% | · |
| AVBP | $854M | -4.7 | · | · | -59.7% | · |
| ORIC | $806M | -5.6 | · | · | -36.5% | · |
| DMRA | · | · | 38.3% | -17981.1% | -167.0% | · |
| REPL | $633M | -2.3 | · | · | -146.2% | · |
| MNKD | $1.75B | 283.5 | 22.2% | 1.7% | -11.1% | · |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.